Does Use of Androgen Deprivation Therapy (ADT) in Men With Prostate Cancer Increase the Risk of Sarcopenia?

Calcified Tissue International - United States
doi 10.1007/s00223-019-00586-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men With Prostate Cancer

Journal of Cancer
Oncology
2014English

Risk of the "Androgen Deprivation Syndrome" in Men Receiving Androgen Deprivation for Prostate Cancer

Archives of Internal Medicine
2006English

Association Between Androgen Deprivation Therapy Use and Diagnosis of Dementia in Men With Prostate Cancer

JAMA network open
Medicine
2019English

Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2016English

Quality of Life Decrements in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

Clinical Endocrinology
EndocrinologyMetabolismDiabetes
2016English

Psychological Distress in Men With Prostate Cancer Receiving Adjuvant Androgen-Deprivation Therapy

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2013English

Androgen Deprivation Therapy for Prostate Cancer and Risk of Dementia

BJU International
Urology
2019English

Use of Androgen Deprivation Therapy in Prostate Cancer: Indications and Prevalence

Asian Journal of Andrology
MedicineUrology
2012English

Screening for Androgen Deprivation Therapy Related Side Effects in Men With Prostate Cancer

English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy